Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07108283 · ClinicalTrials.gov registry record · Phase 2
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
A Phase 2 study of Non-segmental Vitiligo, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT07108283: Recruiting Phase 2 study of Non-segmental Vitiligo, sponsored by Takeda.
NCT07108283 is a Phase 2 study of Non-segmental Vitiligo that is actively recruiting participants, run by Takeda. The registered enrollment target is 200 participants, below the 248-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07108283, a Phase 2 study of Non-segmental Vitiligo, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches). The main aim of this study is to learn how safe zasocitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months. During the study, participants will visit their study clinic 11 times.
Primary Outcome
The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.5, with higher scores indicating more severe disease. Negative changes from baseline indicate improvement. This is recorded as either Yes (achieved \>= 75% improvement) or No (did not achieve).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Zasocitinib
Study Locations (20)
California
- First OC Dermatology - Fountain Valley
- Center for Dermatology Clinical Research, Inc. - Fremont
- The Vitiligo & Pigmentation Institute of Southern California - Los Angeles
- UC Davis Department of Dermatology - Sacramento
- Therapeutics Clinical Research - San Diego
Florida
- Encore Medical Research of Boynton Beach LLC. - Boynton Beach
- San Marcus Research Clinic, Inc. - Miami Lakes
- Advanced Clinical Research Institute (ACRI) - Tampa
- Encore Medical Research of Weston LLC - Weston
New York
- Mount Sinai - New York
- Weill Cornell Medicine - New York
- Markowitz Medical dba Optiskin - New York
Louisiana
- DelRicht Research - Dermatology - Baton Rouge
- DelRicht Research (Audubon Dermatology) - New Orleans
Arkansas
- Dermatology Trial Associates - Bryant
Maryland
- Lawrence J Green LLC - Rockville
Michigan
- Hamzavi Dermatology - Canton - Canton
Ohio
- Bexley Dermatology (legal entity - Dermatologists of Southwestern Ohio, LLC) - Bexley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2027-11-09 |
| Phase | Phase 2 |
What NCT07108283 shows while recruiting
NCT07108283 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 248-participant average among 9 other Non-segmental Vitiligo trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07108283 names 20 study sites across 10 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT07108283 about?
NCT07108283 is a clinical study titled "A Study of Zasocitinib in Adults With Nonsegmental Vitiligo". Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less...
What is the current status of trial NCT07108283?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-11-03. Estimated completion is 2027-11-09.
What conditions does trial NCT07108283 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT07108283?
The interventions under investigation include: Placebo (OTHER), Zasocitinib (DRUG).
Who is sponsoring clinical trial NCT07108283?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07108283 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07108283's enrollment target sits among peer trials
200 6th of 9 higher than 3 of 9 other Non-segmental Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-segmental Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI